Slimi

Adults: Slimi is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI)>30 kg/m² and overweight patients (BMI >28 kg/m² ) with associated risk factors such as type II diabetes, hyperlipidemia and hypertension. Treatment with Slimi should be discontinued after 12 weeks in patients who have not lost at least 5% of their body weight as measured at the start of drug therapy.

Adolescents (12 years & older): Obese adolescents should be treated with Slimi only if an adequate reduction of body weight cannot be achieved by means of diet & increased physical activity. Treatment with Slimi should be considered in particular if complications of obesity are present.

Adults: Slimi is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI)>30 kg/m² and overweight patients (BMI >28 kg/m² ) with associated risk factors such as type II diabetes, hyperlipidemia and hypertension. Treatment with Slimi should be discontinued after 12 weeks in patients who have not lost at least 5% of their body weight as measured at the start of drug therapy.

Adolescents (12 years & older): Obese adolescents should be treated with Slimi only if an adequate reduction of body weight cannot be achieved by means of diet & increased physical activity. Treatment with Slimi should be considered in particular if complications of obesity are present.

Adults: Slimi is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI)>30 kg/m² and overweight patients (BMI >28 kg/m² ) with associated risk factors such as type II diabetes, hyperlipidemia and hypertension. Treatment with Slimi should be discontinued after 12 weeks in patients who have not lost at least 5% of their body weight as measured at the start of drug therapy.

Adolescents (12 years & older): Obese adolescents should be treated with Slimi only if an adequate reduction of body weight cannot be achieved by means of diet & increased physical activity. Treatment with Slimi should be considered in particular if complications of obesity are present.

Adults: Slimi is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI)>30 kg/m² and overweight patients (BMI >28 kg/m² ) with associated risk factors such as type II diabetes, hyperlipidemia and hypertension. Treatment with Slimi should be discontinued after 12 weeks in patients who have not lost at least 5% of their body weight as measured at the start of drug therapy.

Adolescents (12 years & older): Obese adolescents should be treated with Slimi only if an adequate reduction of body weight cannot be achieved by means of diet & increased physical activity. Treatment with Slimi should be considered in particular if complications of obesity are present.

Adults: Slimi is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI)>30 kg/m² and overweight patients (BMI >28 kg/m² ) with associated risk factors such as type II diabetes, hyperlipidemia and hypertension. Treatment with Slimi should be discontinued after 12 weeks in patients who have not lost at least 5% of their body weight as measured at the start of drug therapy.

Adolescents (12 years & older): Obese adolescents should be treated with Slimi only if an adequate reduction of body weight cannot be achieved by means of diet & increased physical activity. Treatment with Slimi should be considered in particular if complications of obesity are present.

Adults: Slimi is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI)>30 kg/m² and overweight patients (BMI >28 kg/m² ) with associated risk factors such as type II diabetes, hyperlipidemia and hypertension. Treatment with Slimi should be discontinued after 12 weeks in patients who have not lost at least 5% of their body weight as measured at the start of drug therapy.

Adolescents (12 years & older): Obese adolescents should be treated with Slimi only if an adequate reduction of body weight cannot be achieved by means of diet & increased physical activity. Treatment with Slimi should be considered in particular if complications of obesity are present.

Adults: Slimi is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI)>30 kg/m² and overweight patients (BMI >28 kg/m² ) with associated risk factors such as type II diabetes, hyperlipidemia and hypertension. Treatment with Slimi should be discontinued after 12 weeks in patients who have not lost at least 5% of their body weight as measured at the start of drug therapy.

Adolescents (12 years & older): Obese adolescents should be treated with Slimi only if an adequate reduction of body weight cannot be achieved by means of diet & increased physical activity. Treatment with Slimi should be considered in particular if complications of obesity are present.

Adults: Slimi is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI)>30 kg/m² and overweight patients (BMI >28 kg/m² ) with associated risk factors such as type II diabetes, hyperlipidemia and hypertension. Treatment with Slimi should be discontinued after 12 weeks in patients who have not lost at least 5% of their body weight as measured at the start of drug therapy.

Adolescents (12 years & older): Obese adolescents should be treated with Slimi only if an adequate reduction of body weight cannot be achieved by means of diet & increased physical activity. Treatment with Slimi should be considered in particular if complications of obesity are present.

Adults: Slimi is indicated in conjunction with a mildly hypocaloric diet for the treatment of obese patients with a body mass index (BMI)>30 kg/m² and overweight patients (BMI >28 kg/m² ) with associated risk factors such as type II diabetes, hyperlipidemia and hypertension. Treatment with Slimi should be discontinued after 12 weeks in patients who have not lost at least 5% of their body weight as measured at the start of drug therapy.

Adolescents (12 years & older): Obese adolescents should be treated with Slimi only if an adequate reduction of body weight cannot be achieved by means of diet & increased physical activity. Treatment with Slimi should be considered in particular if complications of obesity are present.